Santanu Singha

Santanu Singha

Auto-generated profile, based on publicly available information

Santanu Singha

Chemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2021 in Journal of the American Chemical Society
Verified
Journal Article
Open access
SSSantanu Singha
Santanu Singha
MBMichael Buchsteiner
Michael Buchsteiner
GBGiovanni Bistoni
Giovanni Bistoni
RGRichard Goddard
Richard Goddard
AFAlois Fürstner
Alois Fürstner
Heterobimetallic bismuth–rhodium paddlewheel complexes with phenylglycine ligands carrying TIPS-groups at the meta-positions of the aromatic ring exhibit outstanding levels of selectivity in reactions of donor/acceptor and donor/donor carbenes; at the same time, the reaction rates are much faster and the substrate scope is considerably wider than those of previous generations of chiral [BiRh] catalysts. As shown by a combined experimental, crystallographic, and computational study, the new catalysts draw their excellent application profile largely from the stabilization of the chiral ligand sphere by London dispersion (LD) interactions of the peripheral silyl substituents.

21 July 2023 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
SSSameek Singh
Sameek Singh
WTWenzhi Tian
Wenzhi Tian
ZSZachary C. Severance
Zachary C. Severance
SCSantosh K. Chaudhary
Santosh K. Chaudhary
VAViktoriya Anokhina
Viktoriya Anokhina
ACAmit Choudhary
Amit Choudhary
In this review, we highlight bifunctional modalities that perform functions other than degradation and have great potential to revolutionize disease treatment, while also serving as important tools in basic research to explore new aspects of biology.

9 August 2023 in ACS Central Science
Verified
Journal Article
Open access
RPRajaiah Pergu
Rajaiah Pergu
VSVeronika M. Shoba
Veronika M. Shoba
SCSantosh K. Chaudhary
Santosh K. Chaudhary
DGDhanushka N. P. Munkanatta Godage
Dhanushka N. P. Munkanatta Godage
ADArghya Deb
Arghya Deb
ACAmit Choudhary
Amit Choudhary
Chimeric small molecules that induce post-translational modification (PTM) on a target protein by bringing it into proximity to a PTM-inducing enzyme are furnishing novel modalities to perturb protein function. Despite recent advances, such molecules are unavailable for a critical PTM, tyrosine phosphorylation. Furthermore, the contemporary design paradigm of chimeric molecules, formed by joining a noninhibitory binder of the PTM-inducing enzyme with the binder of the target protein, prohibits the recruitment of most PTM-inducing enzymes as their noninhibitory binders are unavailable. Here, we report two platforms to generate phosphorylation-inducing chimeric small molecules (PHICS) for tyrosine phosphorylation. We generate PHICS from both noninhibitory binders (scantily available, platform 1) and kinase inhibitors (abundantly available, platform 2) using cysteine-based group transfer chemistry. PHICS triggered phosphorylation on tyrosine residues in diverse sequence contexts and target proteins (e.g., membrane-associated, cytosolic) and displayed multiple bioactivities, including the initiation of a growth receptor signaling cascade and the death of drug-resistant cancer cells. These studies provide an approach to induce biologically relevant PTM and lay the foundation for pharmacologic PTM editing (i.e., induction or removal) of target proteins using abundantly available inhibitors of PTM-inducing or -erasing enzymes.

21 April 2021 in Helvetica Chimica Acta
Verified
Journal Article
Open access
PDF file
LLLorenz E. Löffler
Lorenz E. Löffler
MBMichael Buchsteiner
Michael Buchsteiner
LCLee R. Collins
Lee R. Collins
FCFabio P. Caló
Fabio P. Caló
SSSantanu Singha
Santanu Singha
AFAlois Fürstner
Alois Fürstner
[Rh2(MEPY)4] is a versatile catalyst for asymmetric synthesis but its preparation requires purification by chromatography on surface‐modified silica. A higher yielding procedure based on a more convenient work‐up is presented herein. Moreover, a much improved method for the preparation of [BiRh(OTfa)4] is described, which makes this heterobimetallic complex readily available. Subsequent exchange of the trifluoroacetate ligands opens access to a so far underappreciated family of (chiral) paddlewheel complexes. While [BiRh] complexes comprising four carboxylate ligands are highly adequate for intermolecular asymmetric cyclopropanation reactions, [BiRh(MEPY)4] as the heterobimetallic cousin of [Rh2(MEPY)4] was found to be surprisingly unreactive; DFT calculations uncover the reasons for this inertia.

5 March 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
RPRajaiah Pergu
Rajaiah Pergu
VSVeronika M. Shoba
Veronika M. Shoba
SCSantosh K. Chaudhary
Santosh K. Chaudhary
DGDhanushka N. P. Munkanatta Godage
Dhanushka N. P. Munkanatta Godage
ADArghya Deb
Arghya Deb
ACAmit Choudhary
Amit Choudhary
Chimeric small molecules that induce post-translational modification (PTM) on a target protein by bringing it in proximity to a PTM-inducing enzyme are furnishing novel modalities to perturb protein function. Despite recent advances, such molecules are unavailable for a critical PTM, tyrosine phosphorylation. Furthermore, the contemporary design paradigm of chimeric molecules, formed by joining a non-inhibitory binder of the PTM-inducing enzyme with the binder of the target protein, prohibits the recruitment of most PTM-inducing enzymes as their non-inhibitory binders are unavailable. Here, we report two platforms to generate phosphorylation-inducing chimeric small molecules (PHICS) for tyrosine phosphorylation. We generate PHICS from both non-inhibitory binders (scantily available, platform 1) and kinase inhibitors (abundantly available, platform 2) using cysteine-based group transfer chemistry. PHICS triggered phosphorylation on tyrosine residues in diverse sequence contexts and target proteins (e.g., membrane-associated, cytosolic) and displayed multiple bioactivities, including initiation of a growth receptor signaling cascade and death of drug-resistant cancer cells. These studies provide an approach to induce biologically relevant PTM and lay the foundation for pharmacologic PTM editing (i.e., induction or removal) on target proteins using abundantly available inhibitors of PTM-inducing or erasing enzymes. TOC:

15 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
RPRajaiah Pergu
Rajaiah Pergu
Sreekanth VedagopuramSreekanth Vedagopuram
Sreekanth Vedagopuram
PKPraveen Kokkonda
Praveen Kokkonda
SLSophia Lai
Sophia Lai
PTPraveen K. Tiwari
Praveen K. Tiwari
ACAmit Choudhary
Amit Choudhary
Dynamic cellular processes often employ protein phosphorylation for rapid information transfer within and between cells. Phosphorylation-inducing chimeric small molecules (PHICS) have been developed for targeted protein phosphorylation by on-demand inducing a kinase-protein pairing. However, widespread application of PHICS has been limited as previously reported PHICS that recruited AMP-activated protein kinase (AMPK) required serum starvation and target protein overexpression, recruited only a few of the potential AMPK complexes, and exhibited poor dose- and temporal control. Herein, we report an AMPK PHICS platform that operates under physiological conditions (i.e., no serum starvation or target overexpression), recruits multiple AMPK complexes, and can induce target protein phosphorylation with dose and temporal control. We demonstrated the utility of this platform for controlling phosphorylations that underlie two dynamic cellular processes, namely oncogenic signaling and phase separation. An AMPK PHICS directed against Bruton’s Tyrosine Kinase (BTK), which is a driver of several B cell malignancies, was effective at inducing the death of drug-resistant cancer cells. Here, PHICS induced inhibitory phosphorylations on BTK and attenuated its oncogenic pathway. Phosphorylation of Liprin-α3 induces phase separation in neurons and is critical for neurotransmitter release. Using AMPK PHICS that phosphorylated Liprin-α3, we induced Liprin-α3 phase separation with dose and temporal control. We envision this PHICS platform to find utility in inducing and controlling protein phosphorylations for basic research and biomedicine. Abstract Figure: